Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter double-blind randomized placebo-controlled phase IIB test-of-concept study to evaluate the safety and efficacy of a three-dose regimen of the Clade B-based Merck adenovirus serotype 5 HIV-1 Gag/Pol/Nef vaccine in HIV-1 uninfected adults in South Africa.

Next Previous
Trial Profile

A multicenter double-blind randomized placebo-controlled phase IIB test-of-concept study to evaluate the safety and efficacy of a three-dose regimen of the Clade B-based Merck adenovirus serotype 5 HIV-1 Gag/Pol/Nef vaccine in HIV-1 uninfected adults in South Africa.

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs V 520 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Phambili

Most Recent Events

  • 15 Oct 2016 Results published in the Vaccine
  • 01 Aug 2016 Status changed from completed to suspended, according to results published in the Journal of Infectious Diseases.
  • 15 Apr 2014 Status changed from suspended to completed, as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top